Comparative evaluation of uterine cancer staging data using two different staging systems, 2001-2005
Linh M Duong1, Umed A Ajani, Reda J Wilson
1Cancer Surveillance Branch, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mail Stop K-53, Atlanta, GA 30341, USA. lduong@cdc.gov
Journal of Registry Management
|August 28, 2010
Summary
The Collaborative Stage Derived Summary Stage 2000 (CS DeSS2000) staging system shows improved accuracy for uterine cancer. Data from 2004-2005 indicate better staging completeness and reliability for uterine cancer cases.
Area of Science:
- Oncology
- Cancer Epidemiology
- Biostatistics
Background:
- Accurate cancer staging is crucial for treatment planning and epidemiological studies.
- The transition from Summary Stage 2000 (SS2000) to Collaborative Stage (CS) staging impacts cancer data interpretation.
- Uterine cancer staging has evolved, necessitating evaluation of new systems.
Purpose of the Study:
- To compare the performance of SS2000 with CS Derived Summary Stage 2000 (DeSS2000) for uterine cancer.
- To assess changes in uterine cancer staging distribution between pre- and post-CS implementation periods (2001-2003 vs. 2004-2005).
- To evaluate the data quality of CS DeSS2000 for uterine cancer staging.
Main Methods:
- Utilized population-based cancer registry data from the Surveillance, Epidemiology, and End Results (SEER) Program and National Program of Cancer Registries (NPCR) for 2001-2005.
- Compared directly coded SS2000 with CS DeSS2000 for uterine cancer cases.
- Analyzed staging shifts by comparing diagnosis years 2001-2003 (pre-CS) with 2004-2005 (post-CS).
Main Results:
- Observed slight decreases in in situ and localized uterine cancer diagnoses, with a corresponding increase in regional and distant stages.
- Reported no regional, not otherwise specified (NOS) uterine cancer cases in the 2004-2005 period, unlike 2001-2003.
- Noted a slight decrease in the percentage of unstaged/unknown uterine cancer cases in the later period.
Conclusions:
- The reduction in unstaged cases and elimination of regional, NOS cases suggest improved uterine cancer staging accuracy post-CS implementation.
- CS DeSS2000 data demonstrate high quality for uterine cancer.
- The findings support the use of CS DeSS2000 data for studying uterine cancer stage distribution.
Related Concept Videos
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...